Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathogenic Roles for RNASET2 in Clear Cell Renal Cell Carcinoma.
Peak T, Tian Y, Patel A, Shaw T, Obermayer A, Laborde J, Kim Y, Johnson J, Stewart P, Fang B, Teer JK, Koomen J, Berglund A, Marchion D, Francis N, Echevarria PR, Dhillon J, Clark N, Chang A, Sexton W, Zemp L, Chahoud J, Wang L, Manley B. Peak T, et al. Among authors: echevarria pr. Lab Invest. 2024 Feb 29;104(5):102041. doi: 10.1016/j.labinv.2024.102041. Online ahead of print. Lab Invest. 2024. PMID: 38431116
Increased spatial coupling of integrin and collagen IV in the immunoresistant clear cell renal cell carcinoma tumor microenvironment.
Soupir AC, Hayes MT, Peak TC, Ospina O, Chakiryan NH, Berglund AE, Stewart PA, Nguyen J, Segura CM, Francis NL, Echevarria PMR, Chahoud J, Li R, Tsai KY, Balasi JA, Peres YC, Dhillon J, Martinez LA, Gloria WE, Schurman N, Kim S, Gregory M, Mulé J, Fridley BL, Manley BJ. Soupir AC, et al. Among authors: echevarria pmr. bioRxiv [Preprint]. 2023 Nov 17:2023.11.16.567457. doi: 10.1101/2023.11.16.567457. bioRxiv. 2023. PMID: 38014063 Free PMC article. Preprint.
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.
Pérez-Valero I, Pasquau J, Rubio R, Rivero A, Santos J, Sanz J, Mariño A, Crespo M, Hernández-Quero J, Iribarren JA, Gutiérrez F, Terrón A, Esteban H, Pérez-Molina JA; GESIDA 7011 Study Group members. Pérez-Valero I, et al. J Antimicrob Chemother. 2018 Sep 1;73(9):2444-2451. doi: 10.1093/jac/dky212. J Antimicrob Chemother. 2018. PMID: 29897573 Free article. Clinical Trial.
Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).
Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Palacios R, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GeSIDA 7011 Study Group. Perez-Molina JA, et al. J Antimicrob Chemother. 2017 Jan;72(1):246-253. doi: 10.1093/jac/dkw379. Epub 2016 Sep 13. J Antimicrob Chemother. 2017. PMID: 27629070 Free article. Clinical Trial.
[Baseline characteristics and changes in treatment after a period of optimization of the patients included in the study EFICAR].
Gómez-Marcos MA, Agudo-Conde C, Torcal J, Echevarria P, Domingo M, Arietaleanizbeascoa M, Sanz-Guinea A, de la Torre MM, Ramírez JI, García-Ortiz L; EFICAR (Ejercicio Físico en IC). Gómez-Marcos MA, et al. Among authors: echevarria p. Aten Primaria. 2016 Mar;48(3):166-74. doi: 10.1016/j.aprim.2015.04.005. Epub 2015 Jul 2. Aten Primaria. 2016. PMID: 26142266 Free PMC article. Clinical Trial. Spanish.
29 results